Oral, nasal and pulmonary dosage formulations of copolymer 1

Details for Australian Patent Application No. 2001238469 (hide)

Owner Yeda Research and Development Co., Ltd.

Inventors Linenberg, Milka; Joubran, Remon F.; Riven-Kreitman, Rivka; Gilbert, Adrian; Cohen-Vered, Sharon

Agent Davies Collison Cave

Pub. Number AU-B-2001238469

PCT Pub. Number WO01/60392

Priority 60183666 18.02.00 US; 09507188 18.02.00 US

Filing date 16 February 2001

Wipo publication date 27 August 2001

Acceptance publication date 3 November 2005

International Classifications

A61K 038/00 Medicinal preparations containing peptides

Event Publications

12 June 2003 Amendment Made

  The nature of the amendment is: Amend the invention title to read Oral, nasal and pulmonary dosage formulations of copolymer 1

3 November 2005 Application Accepted

  Published as AU-B-2001238469

2 March 2006 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 02 Feb 2006. Address for service in Australia - Davies Collison Cave Level 15 1 Nicholson Street MELBOURNE VIC 3000

2 March 2006 Standard Patent Sealed

24 August 2006 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 02 Feb 2006 2002

27 September 2007 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001238470

2001238468-Aspirin-triggered lipid mediators